An experimental six-strain Lyme disease vaccine developed by Pfizer has shown over 70% efficacy in individuals aged 5 years ...
An experimental six-strain Lyme vaccine has demonstrated more than 70% efficacy in preventing Lyme disease in people aged ...
OPUS-2 Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine Designed to Provide ...
Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its ...
Lyme disease infects hundreds of thousands of people each year and now scientists may be on the verge of a breakthrough with ...
If approved, the Pfizer-Valneva vaccine could become highly sought-after as Lyme disease surges in the Hudson Valley.
Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme ...
An experimental vaccine for Lyme disease is broadly effective, pharmaceutical companies Pfizer and Valneva announced Monday; ...
In March 2026, Pfizer and partner Valneva reported that their investigational 6‑valent OspA-based Lyme disease vaccine ...
Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above -- The investigational vaccine candidate was well tolerated ...
Valneva and Pfizer's three-dose shot targets the outer surface protein A (OspA) of the Borrelia burgdorfii bacteria that ...
Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results